Representative Mike Shelton donates his bone marrow to help a fellow citizen:
"Cancer had a hold on Patrice Tillman for nearly two years when doctors came to her with what could have been life-threatening news.
“Well, we don't have a match,” they said.
Tillman, now a healthy 31-year-old, was on her second relapse with Hodgkin's lymphoma. Her first marrow treatment was with her own bone marrow. Yet the cancer snapped back six months later.
Tillman needed a peripheral blood stem cell transplant from someone else this time. Since her siblings weren't a match, she was desperate for a lifesaving transplant from a stranger.
But the Arizona woman is black, and only 7 percent of the potential donors worldwide who register with “Be The Match” are black. She was very sick, and she began what doctors hoped wouldn't be the last wait of her life.
She didn't give up, though, because she'd already had her “miracle baby” in 2005, when the cancer and treatment had seemed to eliminate all chances of having another child. Surely, more miracles were ahead."
Read More: http://newsok.com/oklahoma-legislators-donation-helps-save-ariz.-womans-...
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...